As shown in Fig. 4, in both models, systemic administration of 4-1BB antibody targeted KLF2 (+4-1BB-KLF2), but not 4-1BB targeted control (+4-1BB-Ctrl), siRNA enhanced vaccine-induce antitumor immunity, measured as tumor progression and survival. This evidence concerns the gene KLF2 and neoplasm.